Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more
Camurus AB (CAMX) - Total Liabilities
Latest total liabilities as of December 2025: Skr504.56 Million SEK
Based on the latest financial reports, Camurus AB (CAMX) has total liabilities worth Skr504.56 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Camurus AB - Total Liabilities Trend (2011–2025)
This chart illustrates how Camurus AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Camurus AB Competitors by Total Liabilities
The table below lists competitors of Camurus AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chengdu Wintrue Holding Co Ltd
SHE:002539
|
China | CN¥16.17 Billion |
|
BRDNF
PINK:BRDNF
|
USA | $1.21 Billion |
|
Spectrum Brands Holdings Inc
NYSE:SPB
|
USA | $1.52 Billion |
|
Land and Houses Public Company Limited
OTCGREY:LDHOF
|
USA | $89.12 Billion |
|
Shanghai Phichem Material Co Ltd Class A
SHE:300398
|
China | CN¥1.94 Billion |
|
Shenzhen Ysstech Info-Tech Co Ltd
SHE:300377
|
China | CN¥217.26 Million |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
China | CN¥6.74 Billion |
|
Carmila SA
PA:CARM
|
France | €3.29 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Camurus AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 10.15 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Camurus AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Camurus AB (2011–2025)
The table below shows the annual total liabilities of Camurus AB from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr504.56 Million | +7.97% |
| 2024-12-31 | Skr467.33 Million | +12.66% |
| 2023-12-31 | Skr414.82 Million | +33.46% |
| 2022-12-31 | Skr310.82 Million | +33.40% |
| 2021-12-31 | Skr232.99 Million | +18.47% |
| 2020-12-31 | Skr196.66 Million | +40.06% |
| 2019-12-31 | Skr140.41 Million | +24.92% |
| 2018-12-31 | Skr112.40 Million | +23.61% |
| 2017-12-31 | Skr90.93 Million | +20.67% |
| 2016-12-31 | Skr75.36 Million | -57.13% |
| 2015-12-31 | Skr175.79 Million | +108.75% |
| 2014-12-31 | Skr84.21 Million | +36.69% |
| 2013-12-31 | Skr61.61 Million | +258.30% |
| 2012-12-31 | Skr17.20 Million | -77.46% |
| 2011-12-31 | Skr76.30 Million | -- |